Intervention, Prognosis and Mechanism of Covid-19 Infection in Patients With Underlying Diseases
NCT ID: NCT05965843
Last Updated: 2023-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
480 participants
OBSERVATIONAL
2023-08-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
1. The clinical characteristics of vulnerable population after Covid-19 infection.
2. Risk factors for severe illness in vulnerable groups after infection with the Covid-19.
3. The impact of Covid-19 infection on the progression of underlying diseases.
Information of participants will be collected such as gender, age, underlying diseases, medication status, vaccination status, clinical and biochemical indicators.
Researchers will compare the mild and severe outcomes after Covid-19 infection to identify the "truly vulnerable" population and explore the potential mechanism and intervention for these population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Clinical Features of Patients With Autoimmune Liver Disease Complicated With Covid-19 and the Immune Mechanism Affecting Prognosis
NCT06099626
Autoimmunity Contributes to the Severe Progression of COVID-19
NCT04967781
Microbiome Translocation in Different Circulatory Compartments in Decompensated Cirrhosis
NCT04195724
Neutralizing Antibody Level After COVID-19 Vaccination
NCT05083026
UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease
NCT05812612
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
chronic liver disease
No additional interventions for this group.
underling disease
Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.
For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.
More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.
malignant tumor
No additional interventions for this group.
underling disease
Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.
For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.
More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.
autoimmune disease
No additional interventions for this group.
underling disease
Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.
For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.
More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.
medical staff
No additional interventions for this group.
underling disease
Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.
For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.
More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
underling disease
Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.
For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.
More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Enrolled patients need to have basic diseases, including chronic liver disease, chronic kidney disease, chronic lung disease, solid tumors, AIDS, rheumatic immune diseases, diabetes, etc.
3. When entering the group, patients with new crowns need to be confirmed by evidence of a positive test for new coronavirus nucleic acid (CT value \<35) or a positive test for new coronavirus antigen.
Exclusion Criteria
2. Positive pregnancy test during lactation or screening period.
3. Subjects who, in the investigator's opinion, have other factors that are not suitable for participating in this study.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peng Hu, PhD.
Role: STUDY_DIRECTOR
The Second Affiliated Hospital of Chongqing Medical University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023IITXG01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.